American Society of Hirudotherapy

Dilemmas in the diagnosis and management of antiphospholipid syndrome

Narrative review with two illustrative cases published in Journal of thrombosis and haemostasis : JTH (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportClinical LiteratureDrug DevelopmentManning et al. · Journal of thrombosis and haemostasis : JTH, 2024

Abstract

Antiphospholipid syndrome (APS) is characterized by thrombosis (which may be venous, arterial, or microvascular) and/or pregnancy morbidity in association with persistently positive antiphospholipid antibodies. Although thrombosis and pregnancy morbidity are the main clinical criteria for a diagnosis of APS in the revised Sapporo (Sydney) criteria, recently published American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for APS have significantly refined the diagnostic algorithm to include a scoring system clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular thrombosis, obstetric, cardiac valve, and hematologic). Diagnosis of APS is complicated by the fact that significant heterogeneity exists in patients' clinical presentation, underlying vascular risk factors, and methods of detecting antiphospholipid antibodies. Despite the autoimmune nature of APS, anticoagulation remains the main strategy for secondary prevention of thrombosis. Furthermore, optimal antithrombotic treatment in APS patients with arterial thrombosis remains controversial due to a paucity of data from randomized controlled studies. In this paper, we present 2 cases and highlight the diagnostic and therapeutic challenges they pose and how we approach them in the light of current evidence.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleReview
Indexed MeSH termsFemaleHumansMalePregnancyAntibodies, AntiphospholipidAnticoagulantsAntiphospholipid SyndromePredictive Value of TestsRisk FactorsThrombosisTreatment Outcome

Summary

Illustrated by two cases, this review discusses diagnostic challenges in antiphospholipid syndrome after new ACR/EULAR classification criteria, and therapeutic uncertainty, noting anticoagulation remains the mainstay for secondary thrombosis prevention while arterial antithrombotic choice is debated.

Context

This review with case presentations examines diagnostic and therapeutic challenges in antiphospholipid syndrome (APS), including clinical heterogeneity, antibody detection difficulties, and controversies in antithrombotic management. The authors discuss how anticoagulation remains the main strategy for secondary prevention of thrombosis in APS, while optimal treatment for arterial thrombosis remains controversial due to limited randomized controlled trial data. The abstract contains no mention of leeches, hirudotherapy, hirudin, or leech-derived anticoagulants. The article focuses entirely on conventional pharmaceutical management and classification criteria.

Citation

Reference (Vancouver style)

Manning JE, Arachchillage DJ. Dilemmas in the diagnosis and management of antiphospholipid syndrome. J Thromb Haemost. 2024;22(8):2156-2170. doi:10.1016/j.jtha.2024.03.027. PMID: 38705387

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.